{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T23:53:39Z","timestamp":1785887619727,"version":"3.56.0"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T00:00:00Z","timestamp":1785801600000},"content-version":"vor","delay-in-days":3,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>MECOM rearrangements (MECOM-r) are high-risk events in myeloid neoplasms often cryptic or incompletely characterized by conventional karyotype analysis. We used optical genome mapping (OGM) to define the frequency and spectrum of MECOM-r in an unselected, consecutively collected cohort of individuals with high-grade myeloid neoplasms (HGMNs) and compared these findings with standard cytogenetic approaches.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A total of 252 HGMN specimens, including 224 with definitive diagnoses of acute myeloid leukemia, were processed over a 2-year period using OGM, G-banded karyotyping and, in some cases, reflex fluorescence in situ hybridization (FISH) for the MECOM locus. Cases were retrospectively reviewed to determine whether the identification of MECOM-r by OGM refined diagnosis and\/or prognosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Our diagnostic workflow identified MECOM-r in 12 cases (4.7%), only 6 of which were identified by combined karyotype and FISH analyses, the latter for suspected chromosome 3 abnormalities. The remaining 6 cases were cryptic due to normal karyotypes, highly complex karyotypes lacking apparent chromosome 3 involvement, or culture failure and thus were identified by OGM and reflex FISH. Furthermore, OGM clarified complex architectures, resolved genetic alterations, and identified diverse partner loci, including GATA2, THADA, MYC, PHACTR1, MB21D2, XR_001744423.2, IL12A-AS1, TRIM59, CDK6, and MSI2. Detection of these structural alterations prompted diagnostic and\/or risk reclassification in 5 cases.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Optical genome mapping doubled the detection rate and improved the structural resolution of MECOM-r by identifying rearrangements incompletely resolved or missed by conventional cytogenetics. Implementation of OGM showed that MECOM-r can be cryptic and frequently overlooked, highlighting the value of high-resolution testing in HGMNs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ajcp\/aqag087","type":"journal-article","created":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T13:20:00Z","timestamp":1783084800000},"source":"Crossref","is-referenced-by-count":0,"title":["Optical genome mapping refines diagnosis of high-grade myeloid neoplasms through detection of\n                    <i>MECOM<\/i>\n                    rearrangements cryptic to\u00a0conventional karyotype"],"prefix":"10.1093","volume":"166","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8291-5233","authenticated-orcid":false,"given":"Nicolas","family":"Salcedo-Porras","sequence":"first","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Faculty of Medicine, University of British Columbia , Vancouver, BC,","place":["Canada"]},{"name":"Cytogenomics Laboratory, Department of Pathology and Laboratory Medicine, Vancouver General Hospital , Vancouver, BC,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-0376-9467","authenticated-orcid":false,"given":"Fatma","family":"AlBulushi","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Faculty of Medicine, University of British Columbia , Vancouver, BC,","place":["Canada"]},{"name":"Cytogenomics Laboratory, Department of Pathology and Laboratory Medicine, Vancouver General Hospital , Vancouver, BC,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3949-0337","authenticated-orcid":false,"given":"Julia N C","family":"Parlow","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Faculty of Medicine, University of British Columbia , Vancouver, BC,","place":["Canada"]},{"name":"Cytogenomics Laboratory, Department of Pathology and Laboratory Medicine, Vancouver General Hospital , Vancouver, BC,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3360-5471","authenticated-orcid":false,"given":"Eric","family":"McGinnis","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Faculty of Medicine, University of British Columbia , Vancouver, BC,","place":["Canada"]},{"name":"Cytogenomics Laboratory, Department of Pathology and Laboratory Medicine, Vancouver General Hospital , Vancouver, BC,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-8523-5166","authenticated-orcid":false,"given":"Tara","family":"Spence","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Faculty of Medicine, University of British Columbia , Vancouver, BC,","place":["Canada"]},{"name":"Cytogenomics Laboratory, Department of Pathology and Laboratory Medicine, Vancouver General Hospital , Vancouver, BC,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,8,4]]},"reference":[{"key":"2026080419261869400_aqag087-B1","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1182\/blood-2015-07-604496","article-title":"Molecular landscape of acute myeloid leukemia in younger adults and its clinical relevance","volume":"127","author":"Grimwade","year":"2016","journal-title":"Blood"},{"key":"2026080419261869400_aqag087-B2","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.cell.2014.02.019","article-title":"A single oncogenic enhancer rearrangement causes concomitant EVI1 and GATA2 deregulation in leukemia","volume":"157","author":"Gr\u00f6schel","year":"2014","journal-title":"Cell"},{"key":"2026080419261869400_aqag087-B3","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.ccr.2014.02.008","article-title":"A remote GATA2 hematopoietic enhancer drives leukemogenesis in inv(3)(q21; q26) by activating EVI1 expression","volume":"25","author":"Yamazaki","year":"2014","journal-title":"Cancer Cell"},{"key":"2026080419261869400_aqag087-B4","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.2217\/fon.15.64","article-title":"3q26\/ EVI1 rearrangements in myeloid hemopathies: a cytogenetic review","volume":"11","author":"De Braekeleer","year":"2015","journal-title":"Future Oncol"},{"key":"2026080419261869400_aqag087-B5","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"key":"2026080419261869400_aqag087-B6","doi-asserted-by":"publisher","first-page":"e188","DOI":"10.1038\/bcj.2014.10","article-title":"Incidence and prognostic significance of karyotypic subgroups in older patients with acute myeloid leukemia: the Swedish population-based experience","volume":"4","author":"Lazarevic","year":"2014","journal-title":"Blood Cancer J"},{"key":"2026080419261869400_aqag087-B7","doi-asserted-by":"publisher","first-page":"3890","DOI":"10.1200\/JCO.2010.29.2771","article-title":"Clinical, molecular, and prognostic significance of WHO Type inv(3)(q21q26.2)\/t(3; 3)(q21; q26.2) and various other 3q abnormalities in acute myeloid leukemia","volume":"28","author":"Lugthart","year":"2010","journal-title":"J Clin Oncol"},{"key":"2026080419261869400_aqag087-B8","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International Consensus Classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"key":"2026080419261869400_aqag087-B9","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"key":"2026080419261869400_aqag087-B10","doi-asserted-by":"publisher","first-page":"59","DOI":"10.3390\/hematolrep17060059","article-title":"MECOM-rearranged acute myeloid leukemia: pathobiology and management strategies","volume":"17","author":"Joshi","year":"2025","journal-title":"Hematol Rep"},{"key":"2026080419261869400_aqag087-B11","doi-asserted-by":"publisher","first-page":"2331","DOI":"10.3324\/haematol.2022.282030","article-title":"Characteristics and clinical outcomes of patients with acute myeloid leukemia with inv(3)(q21q26.2) or t(3; 3)(q21; q26.2)","volume":"108","author":"Richard-Carpentier","year":"2023","journal-title":"Haematologica"},{"key":"2026080419261869400_aqag087-B12","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1002\/gcc.22341","article-title":"Complex chromosomal rearrangements leading to MECOM overexpression are recurrent in myeloid malignancies with various 3q abnormalities","volume":"55","author":"Baldazzi","year":"2016","journal-title":"Genes Chromosomes Cancer"},{"key":"2026080419261869400_aqag087-B13","doi-asserted-by":"publisher","first-page":"458","DOI":"10.3390\/cancers15020458","article-title":"3q26.2\/MECOM rearrangements by pericentric inv(3): diagnostic challenges and clinicopathologic features","volume":"15","author":"Tang","year":"2023","journal-title":"Cancers (Basel)"},{"key":"2026080419261869400_aqag087-B14","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1002\/ajh.26587","article-title":"Optical genome mapping for structural variation analysis in hematologic malignancies","volume":"97","author":"Smith","year":"2022","journal-title":"Am J Hematol"},{"key":"2026080419261869400_aqag087-B15","doi-asserted-by":"publisher","first-page":"1958","DOI":"10.3390\/genes12121958","article-title":"Optical genome mapping in routine human genetic diagnostics\u2014its advantages and limitations","volume":"12","author":"Dremsek","year":"2021","journal-title":"Genes (Basel)"},{"key":"2026080419261869400_aqag087-B16","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1182\/bloodadvances.2022007583","article-title":"Optical genome mapping in acute myeloid leukemia: a multicenter evaluation","volume":"7","author":"Levy","year":"2023","journal-title":"Blood Adv"},{"key":"2026080419261869400_aqag087-B17","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1002\/ajh.27175","article-title":"A framework for the clinical implementation of optical genome mapping in hematologic malignancies","volume":"99","author":"Levy","year":"2024","journal-title":"Am J Hematol"},{"key":"2026080419261869400_aqag087-B18","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jmoldx.2026.01.002","article-title":"Technical validation and prospective clinical utility of optical genome mapping in acute leukemia workup: insights from 200 cases following deployment as a first-line diagnostic test in a tertiary care center","volume":"28","author":"Parlow","year":"2026","journal-title":"J Mol Diagn"},{"key":"2026080419261869400_aqag087-B19","author":"ISCN","year":"2020"},{"key":"2026080419261869400_aqag087-B20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000538512","article-title":"ISCN 2024\u2014an international system for human cytogenomic nomenclature (2024)","volume":"164","author":"ISCN","year":"2024","journal-title":"Cytogenet Genome Res"},{"key":"2026080419261869400_aqag087-B21","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.jmoldx.2016.10.002","article-title":"Standards and guidelines for the interpretation and reporting of sequence variants in cancer","volume":"19","author":"Li","year":"2017","journal-title":"J Mol Diagn"},{"key":"2026080419261869400_aqag087-B22","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1038\/s41436-019-0545-7","article-title":"Technical laboratory standards for interpretation and reporting of acquired copy-number abnormalities and copy-neutral loss of heterozygosity in neoplastic disorders: a joint consensus recommendation from the American College of Medical Genetics and Genomics (ACMG) and the Cancer Genomics Consortium (CGC)","volume":"21","author":"Mikhail","year":"2019","journal-title":"Genet Med"},{"key":"2026080419261869400_aqag087-B23","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1159\/000535684","article-title":"Genome mapping nomenclature","volume":"163","author":"Moore","year":"2023","journal-title":"Cytogenet Genome Res"},{"key":"2026080419261869400_aqag087-B24","doi-asserted-by":"publisher","first-page":"5679","DOI":"10.1038\/s41467-021-25862-3","article-title":"The leukemic oncogene EVI1 hijacks a MYC super-enhancer by CTCF-facilitated loops","volume":"12","author":"Ottema","year":"2021","journal-title":"Nat Commun"},{"key":"2026080419261869400_aqag087-B25","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1182\/blood.2019003701","article-title":"Atypical 3q26\/MECOM rearrangements genocopy inv(3)\/t(3; 3) in acute myeloid leukemia","volume":"136","author":"Ottema","year":"2020","journal-title":"Blood"},{"key":"2026080419261869400_aqag087-B26","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.3324\/haematol.13192","article-title":"EVI1 overexpression in t(3; 17) positive myeloid malignancies results from juxtaposition of EVI1 to the MSI2 locus at 17q22","volume":"93","author":"De Weer","year":"2008","journal-title":"Haematologica"},{"key":"2026080419261869400_aqag087-B27","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.jmoldx.2018.10.005","article-title":"t(3; 8)(q26.2; q24) often leads to MECOM\/MYC rearrangement and is commonly associated with therapy-related myeloid neoplasms and\/or disease progression","volume":"21","author":"Tang","year":"2019","journal-title":"J Mol Diagn"}],"container-title":["American Journal of Clinical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajcp\/article-pdf\/166\/2\/aqag087\/70483629\/aqag087.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajcp\/article-pdf\/166\/2\/aqag087\/70483629\/aqag087.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T23:26:23Z","timestamp":1785885983000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajcp\/article\/doi\/10.1093\/ajcp\/aqag087\/8751334"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,8,4]]}},"URL":"https:\/\/doi.org\/10.1093\/ajcp\/aqag087","relation":{},"ISSN":["0002-9173","1943-7722"],"issn-type":[{"value":"0002-9173","type":"print"},{"value":"1943-7722","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,8]]},"published":{"date-parts":[[2026,8]]},"article-number":"aqag087"}}